COLD AND SINUS NIGHTTIME RELIEF TABLET

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Vedd Meg Most

Letöltés Termékjellemzők (SPC)
08-11-2011

Aktív összetevők:

DOXYLAMINE SUCCINATE; PSEUDOEPHEDRINE HYDROCHLORIDE; ACETAMINOPHEN

Beszerezhető a:

VITA HEALTH PRODUCTS INC

ATC-kód:

N02BE51

INN (nemzetközi neve):

ACETAMINOPHEN, COMB EXCL PSYCHOLEPTICS

Adagolás:

6.25MG; 30MG; 500MG

Gyógyszerészeti forma:

TABLET

Összetétel:

DOXYLAMINE SUCCINATE 6.25MG; PSEUDOEPHEDRINE HYDROCHLORIDE 30MG; ACETAMINOPHEN 500MG

Az alkalmazás módja:

ORAL

db csomag:

12/24

Recept típusa:

OTC

Terápiás terület:

MISCELLANEOUS ANALGESICS AND ANTIPYRETICS

Termék összefoglaló:

Active ingredient group (AIG) number: 0337541001; AHFS:

Engedélyezési státusz:

APPROVED

Engedély dátuma:

2012-05-02

Termékjellemzők

                                Page 1 of 66
PRODUCT MONOGRAPH
COLD + SINUS NIGHTTIME
Ibuprofen 200 mg, Pseudoephedrine Hydrochloride 30 mg
and Chlorpheniramine Maleate 2 mg
Tablets
Analgesic/Antipyretic/Nasal Decongestant/Antihistamine
Vita Health Products Inc.
Date of Revision:
150 Beghin Avenue
October 31, 2011
Winnipeg, Manitoba Canada, R2J 3W2
Control# 149333
Page 2 of 66
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT
INFORMATION.......................................................................3
INDICATIONS AND CLINICAL USE
............................................................................3
CONTRAINDICATIONS..................................................................................................3
WARNINGS AND PRECAUTIONS
................................................................................5
ADVERSE
REACTIONS................................................................................................12
DRUG INTERACTIONS
................................................................................................20
DOSAGE AND ADMINISTRATION
............................................................................24
OVERDOSAGE...............................................................................................................25
ACTION AND CLINICAL
PHARMACOLOGY...........................................................28
STORAGE AND STABILITY
........................................................................................33
SPECIAL HANDLING
INSTRUCTIONS......................................................................33
DOSAGE FORMS, COMPOSITION AND
PACKAGING............................................33
PART II: SCIENTIFIC INFORMATION
................................................................................34
PHARMACEUTICAL
INFORMATION........................................................................34
CLINICAL TRIALS
..............................................................
                                
                                Olvassa el a teljes dokumentumot
                                
                            

Dokumentumok más nyelveken

Termékjellemzők Termékjellemzők francia 28-10-2011